BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

 

 

 

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) interview with CEO, Chaim Lebovits, discussing the company's advancements in developing stem cell therapies to treat neurodegenerative diseases. The company's pipeline includes a lead indication for ALS- Amyotrophic Lateral Sclerosis (Lou Gehrig's disease), now in Phase III FDA clinical trials.

BrainStorm's technology is based on using the patients own stem cells, extracted from bone marrow, which are then grown in proprietary conditions, converting them into "biological factories" secreting a variety of neurotrophic factors (NTFs). These stem cells are then re-injected into the patient . . .

This content is available to members only.

If you are an existing member, please LOGIN

Note a member? Sign up for a FREE trial account ($195 per month value), and get immediate access. Free offer expires May 29, 2019.

Register New Account

Free Membership

.

Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2
subscribe@wallstreetreporter.com.